BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immunotech Laboratories Appoints New VP of Business Development


4/15/2013 9:28:57 AM

MONROVIA, CA--(Marketwired - April 15, 2013) - Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) announces the company has appointed Blaine Nabors as VP of Business Development.

Immunotech President & Founder Harry Zhabilov today announced the appointment of Blaine Nabors as Immunotech's VP of Business Development.

Commencing April 08, 2013, Blaine Nabors reached an agreement with Immunotech for the position VP of Business Development.

The position includes day-to-day operations along with assistance for the business marketing strategy and development along with brand marketing recognition. Additional duties will include assistance and communication for the FDA Strategy & Interaction, Regulatory Planning & Execution, Product Development and its Commercialization.

Active involvement in development of a marketing strategy for prospective clients along with continued maintenance of public relations while reviewing, updating and guidance in creating a marketing plan that will generate relationships with Bio-medical companies within the same sector.

Mr. Nabors stated, "I'm very pleased to accept this position offered by Immunotech laboratories. This is such an amazing creation that can save millions of lives around the world. I'm honored to be a part of such a revolutionary proprietary treatment of debilitating infectious diseases. As we move forward to bringing this recognition to the general public through the FDA process, I look forward to what lies ahead for Immunotech laboratories and its further development for all. "

About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.


Company Contact
Email Contact

Public Relations
The Nabors Group
713-875-9200
E-mail: Email Contact
www.facebook.com/Naborsgroup

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES